Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW5004 + Enzalutamide in mCRPC
NCT06702995Phase 2Recruiting
- Sponsor
- Evopoint Biosciences
- Start
- Apr 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of igermetostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Evopoint Biosciences. Started Apr 2023; status: recruiting.
02
Drugs
igermetostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06702995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06702995.